JOINT COMMERCIALIZATION AGREEMENT by and between GENMAB A/S and SEAGEN INC. Dated as of October 19, 2020Joint Commercialization Agreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations • New York
THIS JOINT COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of October 19, 2020 (the “Effective Date”), by and between GENMAB A/S, a Danish corporation (“Genmab”), and SEAGEN INC. (f/k/a SEATTLE GENETICS, INC.), a Delaware corporation (“SGI”). Genmab and SGI are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
BetweenJoint Commercialization Agreement • March 8th, 2000 • Dendreon Corp • California
First Amendment to the Joint Commercialization Agreement 2 “4.3 Taxes. 4.3.1 Tax Partnership. Each Party understands, acknowledges and agrees that to the extent the Parties are sharing Net Profits and Net Losses pursuant to Section 4.1.1 with respect...Joint Commercialization Agreement • July 29th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances) • California
JOINT COMMERCIALIZATION AGREEMENTJoint Commercialization Agreement • March 10th, 2023 • Cingulate Inc. • Pharmaceutical preparations • Delaware
This Joint Commercialization Agreement (this “Agreement”) is made on March 7th 2023 (the “Effective Date”) by and between Indegene, Inc., a Delaware corporation having its place of business at Suite 104, 150 College Road W, Princeton, NJ 08540 (hereinafter referred to as “Indegene”) and Cingulate Therapeutics LLC, a Delaware limited liability company having its corporate office at 1901 W 47th Place, 3rd Floor, Kansas City, KS 66205 (hereinafter referred to as “Cingulate”). Indegene and Cingulate may be referred to individually as a “Party” and together referred to as the “Parties”. Capitalized terms in the Agreement not otherwise defined shall have the meaning set forth in Section 1 below.
JOINT COMMERCIALIZATION AGREEMENTJoint Commercialization Agreement • July 16th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • California
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
